Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
As seen in Vogue
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
These panels help identify what your body needs so you can make more informed decisions about your health
Our formula combines GHK-Cu with three additional active compounds: tretinoin (prescription-strength vitamin A derivative) for cell turnover and collagen synthesis, estriol for skin elasticity and hydration, and niacinamide for barrier function and inflammation control
Cheng FJ, Wang CH, Pan HY, Chen CC, Huang WT, Li SH, et al
J AOAC Int
US$ 26.42
US$ 26.80
US$ 29.69
US$ 29.61
US$ 23.21
US$ 26.15
US$ 28.12
US$ 20.09
US$ 22.64
US$ 25.42
US$ 28.91
US$ 29.81
US$ 21.24
